A Retrospective, Single-center study to evaluate the long-term Bleeding events after Everolimus-Eluting Stent Implantation (Xience V)
Latest Information Update: 14 Jan 2022
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis; Heart failure; Ischaemic stroke; Myocardial infarction; Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Nov 2021 Diabetic mellitus patients were pooled from this study to evaluate the impact of ischemic and bleeding risk factors on long-term clinical outcomes of patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) with everolimus-eluting stents, published in the Catheterization and Cardiovascular Interventions
- 16 Sep 2019 New trial record
- 07 Sep 2019 Results published in the Circulation Journal